CytoDyn Inc. (OTCMKTS:CYDY) Files An 8-K Regulation FD Disclosure
Item7.01 Regulation FD Disclosure.
On April17, 2017, the Company issued a press release relating to
the announcement described in Item8.01 below, a copy of which is
furnished as Exhibit 99.1 to this Form 8-K.
Item8.01. Other Events
On April17, 2017, the Company announced that its application for
Orphan Drug Designation was not granted by the Office of Orphan
Products Development of the U.S. Food and Drug and
Administration.
Item9.01. Financial Statements and Exhibits.
| (d) |
Exhibit No. |
Description. |
||
| 99.1 | Press Release, dated April 17, 2017 |
About CytoDyn Inc. (OTCMKTS:CYDY)
CytoDyn Inc. is a clinical-stage biotechnology company. The Company is focused on the clinical development and commercialization of humanized monoclonal antibodies to treat Human Immunodeficiency Virus (HIV) infection. The Company’s lead product candidate, PRO 140, belongs to a class of HIV therapies known as entry inhibitors that block HIV from entering into and infecting certain cells. The Company’s product pipeline also includes Cytolin and CytoFeline. Cytolin is a mouse monoclonal antibody developed to identify a specific type of immune cell called a cytotoxic T cell, or cytotoxic T lymphocyte (CTL). CytoFeline is an anti-lymphocyte function-associated antigen-1 (LFA-1) antibody for the treatment of Feline Immunodeficiency Virus (FIV) infection. PRO 140 blocks HIV from entering a cell by binding to a molecule called C-C chemokine receptor type 5 (CCR5). The Company has finished Phase II clinical trials for PRO 140 with demonstrated antiviral activity in man. CytoDyn Inc. (OTCMKTS:CYDY) Recent Trading Information
CytoDyn Inc. (OTCMKTS:CYDY) closed its last trading session up +0.010 at 0.700 with 156,969 shares trading hands.
